Evaluation of Thyroid Function in Patients With Chronic Kidney Disease

Rio de Janeiro State University44 enrolled

Overview

A higher prevalence of thyroid disease has been associated with chronic kidney disease (CKD), and subclinical hypothyroidism seems to be the most common dysfunction. The aim is to evaluate thyroid function and autoimmunity in patients with CKD stages 3, 4 and 5. Cross-sectional study to be carried out on patients with stages 3 and 4 in a Nephrology outpatient clinic. Thyroid function is evaluated by measuring thyroid stimulating hormone (TSH), free thyroxine, free triiodothyronine and antithyroperoxidase antibodies (TPOAb) levels.

Cross-sectional study to be carried out on patients with stages 3, 4 and 5 in a Nephrology outpatient clinic. Thyroid function is evaluated by measuring thyroid stimulating hormone (TSH), free thyroxine, free triiodothyronine and antithyroperoxidase antibodies (TPOAb) levels. Free Thyroxine (FT4) will be measured by liquid chromatography tandem mass spectrometry and electrochemiluminescence immunoassay in order to compare methods in this population. The glomerular filtration rate was estimated (eGFR) by the Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI), and the CKD stages were defined according to the Kidney Disease Improving Global Outcomes directives (KDIGO).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Chronic Kidney Disease Thyroid Dysfunction

Interventions

Thyroid functionDIAGNOSTIC_TEST

laboratorial thyroid tests

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria:Patients over 18 years old with CKD stages 3 and 4 were included in the study. \- Exclusion Criteria: 1) acute systemic inflammatory disease; 2) pituitary disease in the past or present; 3) regular treatment with amiodarone, lithium, interferon, immunosuppressive drugs and glucocorticoids; 4) previously diagnosed hypothyroidism and undergoing levothyroxine replacement. \-

Locations (1)

Ana Beatriz Winter Tavares

Petrópolis, Rio de Janeiro, Brazil

Outcomes

Primary Outcomes

Free thyroxine (FT4) levels in chronic kidney disease

Free thyroxine levels through two different methods

Time frame: through study completion, an average of 3 years

TSH levels in chronic kidney disease

TSH levels

Time frame: through study completion, an average of 3 years

Secondary Outcomes

Frequency of thyroid antibodies in chronic kidney disease

antithyroperoxidase and antitireoglobulin antibodies

Time frame: through study completion, an average of 3 years

Free triiodothyronine (FT3) levels in chronic kidney disease

T3 levels

Time frame: through study completion, an average of 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.